



Canadian Hemophilia Society
Help Stop the Bleeding
Société canadienne de l'hémophilie
Arrêtons l'hémorragie

FOR IMMEDIATE RELEASE

**DR. ELIANNA SAIDENBERG IS THIS YEAR'S RECIPIENT OF THE
NOVO NORDISK CANADA - CHS - AHCDC FELLOWSHIP
IN CONGENITAL AND ACQUIRED BLEEDING DISORDERS**

MONTREAL, September 18, 2007 - The Canadian Hemophilia Society (CHS) is pleased to announce that Dr. Elianna Saidenberg is this year's recipient of the NovoNordisk Canada - CHS, Association of Hemophilia Clinic Directors of Canada (AHCDC) Fellowship in Congenital and Acquired Bleeding Disorders.

The Novo Nordisk Canada - Canadian Hemophilia Society - Association of Hemophilia Clinic Directors of Canada Fellowship in Congenital and Acquired Bleeding Disorders was established in the fall of 2001. The goal of this fellowship program is to provide fellows in hematology or other relevant fields the opportunity to acquire clinical or research skills necessary to improve the care and quality of lives of patients with hemophilia and other congenital or acquired bleeding disorders.

Dr. Saidenberg, Chief Resident in Hematology at McMaster University in Hamilton, Ontario, recently received a Fellowship in Transfusion Medicine at the University of Ottawa and has proposed to engage in a study entitled, "Quality Assurance of Special Coagulation Laboratory Practices", under the supervision of Dr. Antonio Giulivi, Medical Director of Transfusion Medicine and Hematology at the Ottawa Hospital-General Campus.

Dr. Saidenberg writes in her fellowship application, "Diagnosis and treatment of patients with abnormalities of coagulation requires the service of a carefully run laboratory. A vital element in providing such service is assurance of the quality of all procedures carried out in the lab." Dr. Saidenberg proposes, "...to review the procedures performed in the special coagulation laboratory of the Ottawa Hospital to ensure quality and assess the need for changes in procedure including utilization of newly available technologies." Additionally, she will attend a co-ordinated hemophilia care clinic and will assess laboratory diagnosis and management of individual patients.

"It's extremely important that people with hemophilia receive the best treatment," said Ian Tu, Director, Biopharmaceuticals, Novo Nordisk Canada Inc. "We are supporting this fellowship so that we can help close the gap between the number of people with hemophilia and the number of physicians who will be needed in the future who understand and treat this disease."

In her outline of proposed training/research, Dr. Saidenberg states that, "Given the necessity of treating many haemostatic defects with human and recombinant blood products, there is a natural connection between transfusion medicine and haemostasis. Incorporated into my fellowship curriculum are opportunities to further knowledge of both clinical and laboratory matters in

disorders of haemostasis. Additionally, core transfusion training will enable me to more fully appreciate the challenges of treating conditions which require blood bank products for treatment. I aim to devote the bulk of my clinical work to clinics specializing in the care of patients with disorders of haemostasis and to incorporate longitudinal training in haemostasis lab techniques and analysis into my two-year curriculum.”

Dr. Saidenberg will also spend several months in Kingston, Ontario where she hopes to have the opportunity to work in the laboratory of Dr. David Lillicrap and gain further understanding of the basis of disorders of coagulation.

This year’s recipient of the NovoNordisk Canada - CHS - AHCDC Fellowship was awarded the McMaster University Medical School Excellence in Teaching Award in 2002, an award that is given in recognition of exceptional teaching achievements.

Dr. Saidenberg states that in the future she hopes to run a specialized multidisciplinary clinic for women with haematological disorders, especially bleeding disorders. This would require co-ordinated care with other specialties, particularly obstetrics and gynecology, but will also require a carefully run coagulation laboratory capable of performing the specialized testing such patients require. She states that the additional training this fellowship will afford will enable her to acquire all the skills needed to run such a program.

Novo Nordisk Canada

Novo Nordisk Canada has a leading position within areas such as coagulation disorders, and manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.

Canadian Hemophilia Society

The Canadian Hemophilia Society is a non-profit organization, striving since 1953 to improve the health and quality of life for all people with inherited bleeding disorders and to find a cure. Its vision is a world free from the pain and suffering of inherited bleeding disorders.

AHCDC

The Association of Hemophilia Clinic Directors of Canada was incorporated in 1994. The goal of the AHCDC is to ensure excellent care for persons with congenital bleeding disorders in Canada through clinical services, research and education.

- 30 -

Contact information:

Chantal Raymond, National Marketing and Communications Coordinator

CANADIAN HEMOPHILIA SOCIETY

1 800 668-2686 / craymond@hemophilia.ca